Wednesday, February 09, 2022 1:32:08 PM
..Warrants granted in the year ended December 31, 2020 were valued using the Black Scholes Model..expected volatility ranging of 411.72%
..Series BB Preferred Stock.. calculated at a price of $1.20..
..Global Stem Cells Group’s operations cover every aspect of the regenerative medicine industry.
..$11,600,000.. have a three (3) year maturity date
..Revenue from viable cell therapy and immune support related products along with physician training was $153,583 from August 19, 2021 to September 30, 2021. The key reason for the increase in revenue was a result of the acquisition of Global Stem Cells Group.
..Other expense decreased by $6,460,049 for the three months ended September 30, 2021
https://www.sec.gov/ix?doc=/Archives/edgar/data/1760026/000121390021066881/f10q0921_mesonumis.htm
Little over a month, $153K from cell-Immune therapy and training during all while Covid disruption.
Recent MSSV News
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 02/12/2024 09:48:31 PM
- Form PRER14C - Information statements • Edgar (US Regulatory) • 02/06/2024 08:59:19 PM
- Meso Numismatics Announces Intention to Undergo Name Change and Authorized Shares Change • InvestorsHub NewsWire • 02/05/2024 12:45:06 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/02/2024 10:14:18 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/11/2024 05:15:24 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/02/2024 08:54:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:06:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 10:03:53 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 06:37:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 03:58:59 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM